HK1200831A1 - A process for preparing 4-4-[([4-chloro-3-(trifluoromethyl) phenyl]aminocarbonyl)amino]-3-fluorophenoxy-n-methylpyridine-2- carboxamide, its salts and monohydrate 4-4-[([4--3-()])]-3--n- -2- - Google Patents

A process for preparing 4-4-[([4-chloro-3-(trifluoromethyl) phenyl]aminocarbonyl)amino]-3-fluorophenoxy-n-methylpyridine-2- carboxamide, its salts and monohydrate 4-4-[([4--3-()])]-3--n- -2-

Info

Publication number
HK1200831A1
HK1200831A1 HK15101433.6A HK15101433A HK1200831A1 HK 1200831 A1 HK1200831 A1 HK 1200831A1 HK 15101433 A HK15101433 A HK 15101433A HK 1200831 A1 HK1200831 A1 HK 1200831A1
Authority
HK
Hong Kong
Prior art keywords
fluorophenoxy
methylpyridine
aminocarbonyl
carboxamide
monohydrate
Prior art date
Application number
HK15101433.6A
Other languages
English (en)
Chinese (zh)
Inventor
Juergen Stiehl
Werner Heilmann
Michael Lgers
Joachim Rehse
Michael Gottfried
Saskia Wichmann
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1200831(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HK1200831A1 publication Critical patent/HK1200831A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Containers And Plastic Fillers For Packaging (AREA)
HK15101433.6A 2010-04-15 2015-02-10 A process for preparing 4-4-[([4-chloro-3-(trifluoromethyl) phenyl]aminocarbonyl)amino]-3-fluorophenoxy-n-methylpyridine-2- carboxamide, its salts and monohydrate 4-4-[([4--3-()])]-3--n- -2- HK1200831A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10004022 2010-04-15

Publications (1)

Publication Number Publication Date
HK1200831A1 true HK1200831A1 (en) 2015-08-14

Family

ID=44070712

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101433.6A HK1200831A1 (en) 2010-04-15 2015-02-10 A process for preparing 4-4-[([4-chloro-3-(trifluoromethyl) phenyl]aminocarbonyl)amino]-3-fluorophenoxy-n-methylpyridine-2- carboxamide, its salts and monohydrate 4-4-[([4--3-()])]-3--n- -2-

Country Status (39)

Country Link
US (5) US8748622B2 (ar)
EP (1) EP2558448B1 (ar)
JP (1) JP5934182B2 (ar)
KR (2) KR20170129276A (ar)
CN (2) CN102947271B (ar)
AR (2) AR081060A1 (ar)
AU (1) AU2011240113B2 (ar)
BR (1) BR112012026117B1 (ar)
CA (1) CA2796238C (ar)
CL (1) CL2012002840A1 (ar)
CO (1) CO6630136A2 (ar)
CR (1) CR20120526A (ar)
CU (2) CU24123B1 (ar)
DK (1) DK2558448T3 (ar)
DO (2) DOP2012000268A (ar)
EC (1) ECSP12012234A (ar)
ES (1) ES2542610T3 (ar)
GT (1) GT201200280A (ar)
HK (1) HK1200831A1 (ar)
HR (1) HRP20150885T1 (ar)
HU (1) HUE026821T2 (ar)
IL (2) IL222348B (ar)
JO (1) JO3158B1 (ar)
MA (1) MA34156B1 (ar)
MX (1) MX2012011734A (ar)
MY (2) MY162359A (ar)
NZ (1) NZ602997A (ar)
PE (2) PE20160838A1 (ar)
PL (1) PL2558448T3 (ar)
PT (1) PT2558448E (ar)
RS (1) RS54219B1 (ar)
RU (1) RU2581585C2 (ar)
SG (2) SG184172A1 (ar)
SI (1) SI2558448T1 (ar)
TN (1) TN2012000492A1 (ar)
TW (2) TWI475992B (ar)
UA (1) UA110613C2 (ar)
UY (2) UY33290A (ar)
WO (1) WO2011128261A1 (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2387812T3 (es) * 2004-09-29 2012-10-02 Bayer Pharma Aktiengesellschaft Forma termodinámicamente estable del tosilato BAY 43-9006
WO2006094626A1 (en) 2005-03-07 2006-09-14 Bayer Healthcare Ag Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
WO2014048881A1 (en) 2012-09-25 2014-04-03 Bayer Pharma Aktiengesellschaft Combination of regorafenib and acetylsalicylic acid for treating cancer
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
US9518020B2 (en) 2013-10-04 2016-12-13 Hetero Research Foundation Process for Regorafenib
CN105218439B (zh) * 2014-06-06 2018-11-20 连云港润众制药有限公司 一种瑞格非尼的晶体及其制备方法
US9790185B2 (en) 2014-07-09 2017-10-17 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN104557689B (zh) * 2015-01-26 2016-06-29 重庆两江药物研发中心有限公司 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法
CN104592105B (zh) * 2015-02-10 2017-01-18 杭州朱养心药业有限公司 瑞戈非尼及其制法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
US20190300484A1 (en) * 2016-01-18 2019-10-03 Natco Pharma Ltd An improved process for the preparation of regorafenib
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术（石家庄）有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN117582495A (zh) 2017-06-02 2024-02-23 拜耳医药保健有限责任公司 用于治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
CN109438336B (zh) * 2018-11-27 2019-11-22 广东安诺药业股份有限公司 一种瑞戈非尼水合物的制备方法
CN109438337B (zh) * 2018-11-27 2019-08-09 广东安诺药业股份有限公司 一种瑞戈非尼中间体的制备工艺
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer
CN114315710B (zh) * 2022-01-07 2024-04-26 江苏豪森药业集团有限公司 一种制备或纯化瑞戈非尼的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
ES2426938T3 (es) 2001-12-03 2013-10-25 Bayer Healthcare Llc Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para tratar cánceres humanos
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
CN1318404C (zh) 2002-02-11 2007-05-30 拜耳制药公司 作为激酶抑制剂的芳基脲类化合物
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) * 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
EP1751139B1 (en) 2004-04-30 2011-07-27 Bayer HealthCare LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
JP5128948B2 (ja) 2004-08-27 2013-01-23 ニッポネックス インコーポレイテッド 癌の治療のための新規な薬剤組成物
ES2387812T3 (es) 2004-09-29 2012-10-02 Bayer Pharma Aktiengesellschaft Forma termodinámicamente estable del tosilato BAY 43-9006
CN101052619B (zh) 2004-09-29 2012-02-22 拜耳先灵制药股份公司 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]苯氧基}-n-甲基吡啶-2-甲酰胺的方法
WO2006094626A1 (en) 2005-03-07 2006-09-14 Bayer Healthcare Ag Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
US20090215835A1 (en) 2005-10-31 2009-08-27 Scott Wilhelm Treatment of cancer with sorafenib
CA2629863A1 (en) 2005-11-14 2007-05-24 Scott Wilhelm Use of sorafenib for the treatment of cancers with acquired resistance to kit inhibitors
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP2081902A1 (en) * 2006-11-09 2009-07-29 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
CA2669158A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
MX2009006579A (es) 2006-12-20 2009-07-22 Bayer Healthcare Llc 4-{4-[({3-terbutil-1-[3-(hidroximetil]fenil]-1h-pirazol-5-il}carb amoil)-amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida asi como precursores y sales de los mismos para el tratamiento de cancer.
JP2010516692A (ja) 2007-01-19 2010-05-20 バイエル・ヘルスケア・エルエルシー 化学療法剤に対し抵抗性を有する癌の処置
EP2129376B1 (en) 2007-01-19 2013-07-24 Bayer HealthCare LLC Treatment of cancers with acquired resistance to KIT inhibitors
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
WO2010048304A2 (en) 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
JP2012526772A (ja) 2009-05-15 2012-11-01 ノバルティス アーゲー ホスホイノシチド３−キナーゼ阻害剤および抗糖尿病性化合物の組合せ剤
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
US20130183268A1 (en) 2010-07-19 2013-07-18 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
SG189038A1 (en) 2010-10-01 2013-05-31 Bayer Ip Gmbh Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
WO2013000909A1 (en) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
CA2840329A1 (en) 2011-06-28 2013-01-03 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing regorafenib
US8841500B2 (en) 2011-11-08 2014-09-23 Chevron U.S.A. Inc. Preparation of alkyl aromatic compounds
JP2014032346A (ja) 2012-08-06 2014-02-20 Japan Display Inc 液晶表示パネル
JO3479B1 (ar) 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب

Also Published As

Publication number Publication date
TW201509415A (zh) 2015-03-16
GT201200280A (es) 2014-07-23
TW201204356A (en) 2012-02-01
KR20130061670A (ko) 2013-06-11
IL222348B (en) 2018-08-30
JP2013523851A (ja) 2013-06-17
US10822305B2 (en) 2020-11-03
PT2558448E (pt) 2015-09-01
NZ602997A (en) 2014-10-31
ECSP12012234A (es) 2012-11-30
DK2558448T3 (en) 2015-08-24
SI2558448T1 (sl) 2015-11-30
MY177066A (en) 2020-09-03
MX2012011734A (es) 2012-12-17
UY33290A (es) 2011-12-01
TN2012000492A1 (en) 2014-04-01
SG10201501221UA (en) 2015-04-29
WO2011128261A1 (en) 2011-10-20
SG184172A1 (en) 2012-11-29
IL222348A0 (en) 2012-12-31
CN102947271A (zh) 2013-02-27
JO3158B1 (ar) 2017-09-20
UY39590A (es) 2022-01-31
HUE026821T2 (en) 2016-07-28
US20170334857A1 (en) 2017-11-23
IL253119A0 (en) 2017-08-31
RU2581585C2 (ru) 2016-04-20
KR101800041B1 (ko) 2017-11-21
PL2558448T3 (pl) 2015-10-30
DOP2012000268A (es) 2012-12-15
IL253119B (en) 2018-03-29
CA2796238A1 (en) 2011-10-20
BR112012026117A2 (pt) 2015-09-08
CO6630136A2 (es) 2013-03-01
HRP20150885T1 (hr) 2015-10-09
MA34156B1 (fr) 2013-04-03
US20170057918A1 (en) 2017-03-02
CU24123B1 (es) 2015-08-27
CN103980191A (zh) 2014-08-13
CL2012002840A1 (es) 2013-01-18
TWI539951B (zh) 2016-07-01
BR112012026117A8 (pt) 2017-12-19
MY162359A (en) 2017-06-15
JP5934182B2 (ja) 2016-06-15
DOP2016000285A (es) 2016-11-30
PE20130181A1 (es) 2013-02-23
US9458107B2 (en) 2016-10-04
BR112012026117B1 (pt) 2022-08-30
RU2012148386A (ru) 2014-05-20
UA110613C2 (uk) 2016-01-25
KR20170129276A (ko) 2017-11-24
US20190144391A1 (en) 2019-05-16
PE20160838A1 (es) 2016-09-24
RS54219B1 (en) 2015-12-31
AR116395A2 (es) 2021-05-05
CR20120526A (es) 2013-03-11
AR081060A1 (es) 2012-06-06
CU20120147A7 (es) 2013-01-30
EP2558448B1 (en) 2015-05-20
ES2542610T3 (es) 2015-08-07
AU2011240113B2 (en) 2014-12-18
US8748622B2 (en) 2014-06-10
CA2796238C (en) 2019-12-31
AU2011240113A1 (en) 2012-10-11
EP2558448A1 (en) 2013-02-20
US20130116442A1 (en) 2013-05-09
CU20140060A7 (es) 2014-10-02
CN102947271B (zh) 2016-11-09
US20140221661A1 (en) 2014-08-07
TWI475992B (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
HK1200831A1 (en) A process for preparing 4-4-[([4-chloro-3-(trifluoromethyl) phenyl]aminocarbonyl)amino]-3-fluorophenoxy-n-methylpyridine-2- carboxamide, its salts and monohydrate 4-4-[([4--3-()])]-3--n- -2-
HK1206261A1 (en) Alpha amino boronic acid derivatives, selective immunoproteasome inhibitors
HK1198822A1 (en) Method for producing a toothbrush, and toothbrush
PL2524658T3 (pl) Ulepszona konfiguracja wyrównania kowadełka i wkładu dla staplera okrężnego
SI2489670T1 (sl) Postopek za proizvodnjo amino kislinskih kelatnih spojin, amino kislinske kelatne spojine in uporaba amino kislinskih kelatnih spojin
BRPI1014760A8 (pt) preparação compreendendo insulina, nicotinamida e um aminoácido
IL225832A0 (en) A method for the preparation of modified isoxazoline compounds and their starting materials 4-chloro, 4-bromo or 4-iodo-benzaldehyde oximes
EP2562152A4 (en) PROCESS FOR PREPARING 2,5-DIMETHYLPHENYL-ACETIC ACID
EP2795048A4 (en) WELL COMPLETION ARRANGEMENT AND METHOD FOR PREPARING A WELL FOR ABANDONMENT
HK1177211A1 (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
EP2725010A4 (en) AMID CONNECTION, MANUFACTURING METHOD AND USE
SI2598479T1 (sl) Postopek za pripravo ramiprila
IL226336A0 (en) A preparation containing insulin, nicotinamide and amino acid
EP2684953A4 (en) MODIFIED AMINO TRANSFERASE, GENE AND METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE AMINO BINDING THEREWITH
HRP20130368T1 (en) New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid
PL2793559T3 (pl) Wkład oraz kubek udojowy
PL2607353T3 (pl) Nowy sposób syntezy iwabradyny i jej soli addycyjnych z kwasem farmaceutycznie dopuszczalnym
EP2669275A4 (en) CAPSULE COMPOUND, ANION REMOVAL AGENT, AND ANION REMOVAL METHOD
ZA201401262B (en) Pures-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1h,-5h-benzo[i,j]quinolizine-2- carboxylic acid l-arginine salt tetrahydrate and a process for its preparation
PL393501A1 (pl) Nowe sole jodoniowe, sposób ich wytwarzania i zastosowanie oraz nowy związek wyjściowy do wytwarzania nowych soli jodoniowych, sposób jego wytwarzania i zastosowanie
EP2699560A4 (en) 5-CARBAMOYL-ADAMANTAN-2-YL AMID DERIVATIVES, PHARMACEUTICALLY ALLOWED SALTS AND METHOD FOR THE PRODUCTION THEREOF
HU1000498D0 (en) New salts and preparation process thereof
GB201116665D0 (en) Process for preparing a particulate solid and a particulate solid